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Abstract
Cystic echinococcosis (CE) is a zoonotic parasitic disease endemic in southern and eastern European countries. The
true prevalence of CE is difficult to estimate due to the high proportion of asymptomatic carriers who never seek
medical attention and to the underreporting of diagnosed cases, factors which contribute to its neglected status. In
an attempt to improve this situation, the European Register of Cystic Echinococcosis (ERCE), was launched in
October 2014 in the context of the HERACLES project. ERCE is a prospective, observational, multicentre register
of patients with probable or confirmed CE. The first ERCE meeting was held in November 2015 at the Italian National
Institute of Health (Istituto Superiore di Sanita, ISS) in Rome, to bring together CE experts currently involved in the
Register activities, to share and discuss experiences, and future developments.
Although the Register is still in its infancy, data collected at the time of writing this report, had outnumbered the
total of national cases reported by the European endemic countries and published by the European Centre for
Disease Prevention and Control in 2015. This confirms the need for an improved reporting system of CE at the
European level. The collection of standardized clinical data and samples is expected to support a more rational,
stage-specific approach to clinical management, and to help public authorities harmonize reporting of CE. A
better understanding of CE burden in Europe will encourage the planning and implementation of public health
policies toward its control.
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Background
Cystic echinococcosis (CE) is a chronic zoonotic in-
fection transmitted to humans through the ingestion
of eggs of the tapeworm Echinococcus granulosus
(sensu lato) (s.l.) shed in the faeces of dogs harbour-
ing the parasite in the intestine. Humans are acciden-
tal intermediate hosts, where the parasite can develop
into fluid-filled cysts (metacestode stage) located
mainly in the liver and lungs [1].
CE has a worldwide distribution, and affects mainly in-
dividuals in poor rural communities in underserved
livestock-breeding areas. In 2010, this disease was
included in the list of 17 Neglected Tropical Diseases
(NTD) prioritized for interventions by the World Health
Organization (WHO; http://www.who.int/neglected_di-
seases/diseases/en/). Current estimates indicate a preva-
lence of 2–3 million global cases and incidence of
around 200,000 new detected infections/year [2]. The
burden of disease was estimated to range between 1 and
3.6 million Disability Adjusted Life Years (DALYs), with
an annual cost of 3 billion US$ accounting for human
treatment and livestock production losses [3, 4].
However, the real prevalence, incidence and burden of
CE are difficult to estimate. This is due to the patchy
distribution of CE within transmission areas, the high
proportion of asymptomatic infected individuals and
symptomatic patients living in resource-poor areas with
logistical and/or economic constraints, who never reach
medical attention, and the unknown effect of underre-
porting of diagnosed cases [5–7]. This last aspect is
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primarily due to lack of CE mandatory notification over-
all. In addition, diagnosis at the species level, differenti-
ating cystic from alveolar echinococcosis in the majority
of Member States is limited. In fact, in Europe the origin
of available data on human CE is very heterogeneous,
and most data are patchy and collected from hospital re-
cords. Therefore, patients receiving medical attention in
an outpatient setting are not registered in hospital re-
cords and are generally not captured.
The difficulties in assessing the burden of disease are
compounded by the peculiar clinical characteristics of CE,
which impact not only the diagnosis but also the treatment
and therefore, the costs associated with the disease. In
humans, echinococcal cysts grow slowly, passing through
different stages, as described by the ultrasound classifica-
tion issued by the WHO Informal Working Group on
Echinococcosis (IWGE) (Fig. 1; [8]). The WHO-IWGE also
indicated that for liver locations, different stages should be
managed with different approaches (chosen among sur-
gery, percutaneous treatments, medical treatment, watch
and wait). However prospective clinical trials to compare
these options are lacking. In addition, this stage-specific
approach is not widely practiced and the management of
the disease is often inappropriate. These conditions make
it difficult to issue evidence-based guidelines for the man-
agement of CE and expose patients and health systems to
unnecessary treatments and costs [7, 9, 10].
Finally, CE is a preventable infection, although elim-
ination is difficult to achieve and, using mathematical
models, is estimated to take between 10 and over
25 years of sustained efforts depending on the com-
bination of interventions implemented and their
coverage [11, 12]. Technological improvements in the
genetic characterization of strains and vaccination
against E. granulosus in animals could increase the ef-
ficiency of control programs, and make them shorter
[13]. It is therefore important to acquire a better un-
derstanding of human epidemiology, burden of infec-
tion and clinical management strategies, to optimize
the control approach.
In 2013, HERACLES (Human cystic Echinococcosis
ReseArch in CentraL and Eastern Societies) a transla-
tional collaborative project funded by the European
Commission under the Seventh Framework Programme
(http://www.Heracles-fp7.eu/) was established. The
main aims of HERACLES are to assess the prevalence
of human abdominal CE through extended ultrasound
surveys in endemic rural areas of Bulgaria, Romania
and Turkey, the endemic countries targeted for screen-
ing, to promote a stage-specific approach to clinical
management through education activities directed at
health care workers, and to improve serological and
molecular diagnostic tools. Within HERACLES, the im-
plementation of an international register of human CE
to provide a tool to record new cases, their treatment,
and the evolution of individual cysts over time, was
identified as essential in order to improve public aware-
ness and clinical management of CE. Indeed, while im-
provement of notification requirements, improved
surveillance, and research to clarify the basis of under-
reporting are essential requirements, they need to be
carried out at the government/central level. The imple-
mentation of an international register based on volun-
tary adhesion of centres where CE patients are
managed, is an essential step to provide data to support
such actions. Additionally, within the HERACLES pro-
ject, the Echino-Biobank was created to host patients’
and parasite samples that can be used in multicenter
analyses approaches for serological and genetic studies,
which often are underpowered when only samples from
individual centres are used.
ERCE is the first CE register, whereas the existent
European Echinococcosis Registry (EurEchinoReg) is ex-
clusively dedicated to the surveillance and reporting of
patients with alveolar echinococcosis, and has a different
structure [14].
The first meeting on ERCE
The first meeting on ERCE was held at the Italian
National Institute of Health (Istituto Superiore di
Fig. 1 Schematic representation of the ultrasound classification of hepatic CE according to WHO-IWGE. CE1, fluid filled active unilocular cyst; CE2,
active cyst with daughter vesicles; CE3a, transitional cyst with detached endocyst; CE3b, daughter vesicles in a solid matrix [although classified as
transitional, this cyst stage is biologically active]; CE4, inactive cyst with solid matrix; CE5, inactive cyst with solid matrix and calcified walls
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Sanita, ISS) in Rome, between 12 and 13 November
2015, to bring together both ERCE active participants
and those interested in joining the Register and to
share and discuss experiences, issues and future de-
velopments. Forty-four participants with expertise in
the management of Echinococcus/echinococcosis from
16 countries (Albania, Austria, Bulgaria, France,
Georgia, Greece, Hungary, Iran, Italy, Palestine,
Poland, Romania, Serbia, Spain, The Netherlands and
Turkey) participated in the meeting (Fig. 2). The
meeting was also supported by the Department of
Control of Neglected Tropical Diseases (WHO, head-
quarters Geneva), a member of the External Advisory
Board of the HERACLES project. During the meeting,
the ERCE and HERACLES activities carried out to
date were presented, as well as overviews on the epi-
demiology of E. granulosus infection in animals and
humans, stage-specific approach to treatment of CE,
percutaneous treatment of CE, and immunodiagnostic
tests for CE diagnosis [7, 15–18]. On the second day
of the meeting, training on the use of the software
developed for the Register was offered, employing an
online trial version of ERCE. Each participant had the
chance to work with the Register, by entering data of
mock patients. During the meeting, the core topics
on ERCE, described below, were illustrated.
ERCE structure
ERCE is a single multicentre database located within the
secured IT network of ISS, in Rome, where patient data,
including demographic information, CE-related clinical
data (unequivocal identification of single cysts, cyst char-
acteristics and treatment administered), and biological
samples collected are recorded (Table 1). Biological
samples (serum, plasma, cyst-derived material, etc.) with
respective clinical information provided by voluntarily ad-
hering centres are stored at the Echino-Biobank, estab-
lished in Salamanca, Spain (IRNASA-CSIC; Instituto de
Recursos Naturales y Agrobiologia de Salamanca – Con-
sejo Superior de Investigaciones Cientificas) within the
HERACLES project. This repository of samples is
Fig. 2 The participants of the European Register of Cystic
Echinococcosis (ERCE). Representatives of the centres from 16
European and Asian countries (Albania, Austria, Bulgaria, France,
Georgia, Greece, Hungary, Iran, Italy, Palestine, Poland, Romania,
Serbia, The Netherlands, Spain and Turkey) at the official launch
meeting on ERCE. The meeting was held at the Italian National
Institute of Health (Istituto Superiore di Sanita, ISS) in Rome, Italy,
between 12 and 13 November 2015
Table 1 Schematic overview of the European Register of Cystic
Echinococcosis (ERCE) features
Patients enrolled in ERCE
− with confirmed or probable CE (direct evidence of infection, imaging-
based diagnosis alone or associated with positive serology)
− in- and out-patients
− all ages and both sexes
− first visit or follow-up visit
Data recorded for each patient
− personal data: year of CE first diagnosis and history of treatments
− clinical data: cyst(s) localization, size and stage, administered
treatment(s)
− data on the biological samples collected (if any)
− ERCE complies with Italian (Italian Personal Data Protection Code n.
196, 2003) and European (2000/C 364/01, and Directive 95/46/EC)
regulations on the protection and use of personal data
− two informed consent forms must be signed by patients at initial
registration to allow:
* their data to be recorded in the Register
* their biological samples to be shipped to the Echino-Biobank
ERCE structure
− single multicenter database located within the secured IT network
of the Italian National Institute of Health (Istituto Superiore di
Sanità, ISS) in Rome
− organized in sheets where patient data are recorded
− each registered patient is automatically given a unique ERCE ID code
− data are uncoupled and anonymized
ERCE users
− physicians working in health centers where patients with CE are
managed
− join ERCE network voluntarily
− are provided with personal credentials to login to the register
− different roles are envisaged:
* the “person in charge” in each centre enters patients’ data
* the “supervisor” in each centre can read only data of his/her centre
* the Register “coordinator” has access to and can download data
from all national centres
Requirements to join ERCE
− to be a physician working in centers where CE patients (in- and
out-patients) are visited
− to get the approval from the Ethics Committee (EC) of each centre/
country involved (although the implementation of the Register is
only observational and does not involve clinical experimentation)
Ownership of data
− data from individual centres belongs to the individual centres
themselves
− the coordinator can only use cumulative data for periodic
presentations on the progress of ERCE
− publication of data requires the consent of the individual centres
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registered as an official biobank collection (registration
number C.0003432) and is managed according to the
European standards for biobanking (Law 1716/201), in-
cluding anonymization of samples through their (-80 °C)
storage in 2D-barcoded tubes that can be scanned and
automatically linked to the corresponding clinical data in
ERCE.
Ethical approval
ERCE was developed by re-structuring and expanding
at international level the Italian Register of CE (RIEC)
implemented in 2012 [19]. RIEC was approved by the
ISS Ethics Committee (Ns Prot. CE/12/347 of May
7th, 2012), which extended its agreement to ERCE
(Prot. PRE-C-915/14 of November 25th, 2014). Since
its inception, more than 845 patients from 24 affili-
ated centres in nine countries (Albania, Austria,
Bangladesh, Bulgaria, Hungary, Italy, Poland, Romania
and Turkey) have been enrolled (Fig. 3). CE patients
identified during the ultrasound surveys carried out
in Bulgaria, Romania and Turkey in 2014 and 2015 as
part of the HERACLES project are also listed in
ERCE, and their biological samples are included in
the Echino-Biobank repository. The Register has re-
cently been extended to extra-European countries.
Aims of ERCE
The European Register of Cystic Echinococcosis (ERCE;
http://www.heracles-fp7.eu/erce.html) was created with
the aim of providing a more appropriate tool for the sur-
veillance of human CE, built to take into account the pe-
culiar features of the infection such as chronicity and case
management often carried out in an outpatient setting,
and to establish a prospective case retrieval to evaluate the
spontaneous or treatment-related evolution of individual
cysts. This will offer the opportunity to study prospectively
and systematically a stage-specific approach to treatment,
rate of adverse reactions, relapse rate and costs of CE in-
fection. Data collected in ERCE will allow national author-
ities and international agencies such as the European
Centre for Disease Prevention and Control (ECDC) to ac-
knowledge the magnitude of the problem by reporting
cases otherwise not captured by systems such as hospital
discharge records. Furthermore, it will offer a prototype
register structure to harmonize data collection and report-
ing of CE including data on the pivotal clinical features of
the infection, to ultimately encourage and support with
data the planning and implementation of public health
policies toward its management and control.
ERCE addresses the research questions concerning the
number of CE patients visiting each affiliated centre,
their geographical origin, their clinical management, and
Fig. 3 Countries currently involved in the European Register of Cystic Echinococcosis (ERCE). In red: countries with ERCE affiliated centres
that received the clearance from ethics committee and enrolled patients so far. Orange: countries with ERCE affiliated centres that
received only the clearance from ethics committee. Yellow: countries interested or in the process of affiliation to ERCE. More information
available at: http://www.heracles-fp7.eu/erce.html
Rossi et al. Parasites & Vectors  (2016) 9:243 Page 4 of 6
the spontaneous or treatment-induced evolution of the
cysts over time. The collection of such data in a consist-
ent, harmonized way will help reduce the difficulties in
clinical decision-making caused by the lack of prospect-
ive studies, which are not affordable at the current rate
of funding for research on CE [3]. It is widely known
that the majority of clinical studies on CE are retrospect-
ive, and underpowered by the small number of homoge-
neous samples that each centre has access to. The
Echino-Biobank, a wide collection of biological samples
with reliable clinical data from CE patients, will support
this action.
Usefulness of ERCE for individual participating centers
Both individual centers and the scientific community
at large will benefit from the data stored in the ERCE
database. The unique ERCE ID assigned to each pa-
tient, together with the possibility of updating patient
records at each follow-up visit, allows the tracking of
new diagnoses, patients referred by other centres,
compliance and lost-to-follow-up rates, demographic
structure and geographical origin of the patient popu-
lation of each centre. From a clinical perspective, the
unequivocal identification of each cyst in the Register
facilitates the follow-up and clinical evaluation of the
evolution of each cyst, either spontaneously or
through treatment induction allowing a better evalu-
ation of the stage-specific outcome of each clinical
management approach. Finally, by participating in the
Echino-Biobank, centres involved in research activities
may benefit from accessing a wide panel of well-
characterized sera and other biological material, per-
forming powerful studies, otherwise difficult to carry
out by using a limited number of samples from single
centres. Access to the samples hosted in the Echino-
Biobank will be evaluated in a project-based frame by
the ethical and scientific committees of the biobank.
Critical issues
The voluntary nature of adhesion to ERCE and the data
recording based on the goodwill of single clinicians will
limit the use of data from ERCE to make estimates on
prevalence and incidence of infection. However,
altogether, the information collected prospectively and
in a consistent way within ERCE will support decisions
regarding the implementation of control programs, of
better designed reporting systems, and the issue of case
management recommendations. A critical evaluation of
data quality will be carried out yearly, and a comprehen-
sive evaluation of the usefulness of the Register will be
carried out after five years.
The sustainability of the Register over time after the
end of HERACLES project is guaranteed, since Registers
at ISS are officially considered as an institutional
commitment currently maintained by dedicated perman-
ent staff for which no funding is needed. The Echino-
BioBank will be sustained over time by the European
Union Reference Laboratory for Parasites (http://
www.iss.it/crlp/).
The HERACLES extended network
This international network was recently created within
the framework of HERACLES collaborative project, and
it extends the capacity of the core partners of the project
(http://www.heracles-fp7.eu/interactive_map.html). The
HERACLES extended Network is currently represented
by more than 40 centres from 23 European and Asian
nations, most of whom are participating in ERCE. The
network includes mostly clinicians dealing with diagno-
sis and clinical management of CE, but also experts on
CE epidemiology, diagnosis, molecular characterization
and control, providing advice and support. The aim of
this network is to support core activities within HERA-
CLES, such as enrolling patients in ERCE, providing
parasitic and human samples to the Echino-Biobank ac-
cording to a standardized protocol, and cooperating in
research studies on serology and molecular epidemiology
of CE. The ultimate goal is to promote health equity on
CE providing common background, tools and access to
biological and medical knowledge for the centres in-
volved in the HERACLES extended Network.
Conclusions
The true number of CE cases in Europe is unknown
mainly due to the lack of mandatory notification re-
quirement. In 2015 the ECDC reported 801 con-
firmed human cases of ‘echinococcosis’ from 14
Member States, but the differentiation between cystic
and alveolar echinococcosis was not available [20]. As
stressed by the European Food Safety Authority [21],
a re-evaluation of the case definition for ‘echinococ-
cosis’ in the current EU decision 2012/506/EU, differ-
entiating these two diseases, will be crucial in order
to collect real epidemiological and clinical data to
manage and track these infections.
The collection of essential clinical data using a
standardized approach will provide valuable informa-
tion on the clinical history of the infection in popula-
tions living in endemic areas. The experience from
ERCE will enable governments, the European Com-
mission and related European agencies such as ECDC,
to harmonize data collection, monitoring and report-
ing of CE, according to EU legislation (Directive
2003/99/CE of the European Parliament). Addition-
ally, samples hosted in the Echino-Biobank will sup-
port evidence-based studies in the diagnosis and
follow-up of CE patients.
Rossi et al. Parasites & Vectors  (2016) 9:243 Page 5 of 6
We encourage other researchers and clinicians around
the world to participate in ERCE, and help the many pa-
tients suffering from a complex and chronic disease that
has been under the radar for too long.
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